胃苏颗粒联合雷贝拉唑三联疗法对慢性胃炎患者血清TGF-β1、EGF表达的影响

Effects of Weisu Granules Combined with Rabeprazole Triple Therapy on the Expression of Serum TGF-β1 and EGF in Patients with Chronic Gastritis

目的探讨慢性胃炎(CG)患者应用胃苏颗粒联合雷贝拉唑三联疗法的治疗效果。方法采用随机数字表法将2020年5月至2022年5月于新余市人民医院就诊的CG患者92例分为两组,每组各46例。对照组予以三联疗法治疗,观察组加用胃苏颗粒治疗,均连续治疗2周。比较两组临床疗效、中医症候积分、血清学指标及安全性。结果观察组临床总有效率较对照组高,中医症候积分及表皮生长因子(EGF)、转化生长因子-β1(TGF-β1)、白介素(IL)-4、IL-10水平较对照组低,差异有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论在雷贝拉唑三联疗法治疗基础上,联合应用胃苏颗粒可增强治疗效果,减轻炎症反应,调节TGF-β1、EGF表达,缓解临床症状,值得推广。

Objective To investigate the therapeutic effect of weisu granules combined with rabeprazole triple therapy in patients with chronic gastritis (CG). Methods Using the random number table method, 92 CG patients who were treated in Xinyu People's Hospital from May 2020 to May 2022 were divided into two groups, with 46 cases in each group. The control group was treated with triple therapy, and the observation group was additionally treated with weisu granules. Both groups were treated for 2 consecutive weeks. The clinical efficacy, TCM symptom scores, serological indexes and safety were compared between the two groups. Results The clinical total effective rate of the observation group was higher than that of the control group, and the TCM symptom score and the levels of epidermal growth factor (EGF), transforming growth factor-β1 (TGF-β1), interleukin (IL)-4 and IL-10 were lower than those of the control group with statistical difference (P<0.05). There was no statistical difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion On the basis of rabeprazole triple therapy, combined application of weisu granules can enhance the therapeutic effect, reduce inflammatory response, regulate the expression of TGF-β1 and EGF, and relieve clinical symptoms, which is worthy of promotion.